EDUCATION

Sept 1995  – July 1998 Ph.D. in Pharmacology

Shanghai Institute of Materia & Medica, Chinese Academy of Sciences, Shanghai, China

Sept 1993 – July 1995 MS in Pharmacology

ZhejiangMedical University, Hangzhou, China

Sept 1989 – July 1993 BS in Department of Pharmacy

      ZhejiangMedical University, Hangzhou, China

RESEARCH ACTIVITIES AND WORKING EXPERIENCE

Professor /Vice dean        Oct 2003 - present

Department of Pharmacology, School of Pharmaceutical Science, Zhejiang University, Hangzhou, Zhejiang, China

Research on drug resistance mechanism in cancer cells

 New Anti-Cancer Drugs

Teach Pharmacology, Clinical Pharmacology and Animal Experiments, etc.

Active Member of American Association for Cancer Research

Visiting Scientist     Nov 2000 – Oct 2003

Keck School of Medicine, University of Southern California, CA, USA     

Research on Effect of Hypoxia on Antagonizing Chemotherapy in Neuroblasoma

Member of American Association for Cancer Research  

Associate Professor / Lecturer        August 1998 – Oct 2000

Department of Pharmacology, School of Pharmaceutical Science, Zhejiang University, Hangzhou, China 

Research on Screening New Drugs for Reproductive Regulation and Ovarian Cancer in vitro and in vivo

Teach Pharmacology, Clinical Pharmacology and Animal Experiments, etc. 

SELECTIVE  PUBLICATIONS

 (*:corresponding autor)

• Cao J, Xu D, Wang D, Wu R, Zhang L, Zhu H, He Q*, Yang B*. ROS-driven Akt dephosphorylation at Ser-473 is involved in 4-HPR-mediated apoptosis in NB4 cells. Free Radic Biol Med. 2009 Sep 1;47(5):536-47.
• Zhang C, Cai TY, Zhu H, Yang L, Jiang H, Dong XW, Hu Y, Lin NM, He Q, Yang B*. Synergistic anti-tumor activity of gemcitabine and ABT-737 in vitro and in vivo through disrupting the interaction of USP9X and Mcl-1. Mol Cancer Ther.10(7):1264-75. 2011 Jul
• Luo PH, He QJ, He XG, Hu YZ, Lu W，Cheng YY, Yang Bo*. Potent antitumor activity of 10-methoxy-9-nitrocamptothecin. Molecular Cancer Therapeutics 2006;5(4):962-8.
• Zheng L, Yang W, Zhang C, Ding WJ, Zhu H, Lin NM, Wu HH, He QJ, Yang B*. GDC-0941 sensitizes breast cancer to ABT-737 in vitro and in vivo through promoting the degradation of Mcl-1. Cancer Lett. 1;309(1):27-36. 2011 Oct
• Zhang C, Wu R, Zhu H, Hu YZ, Jiang H, Lin NM, He QJ, Yang B*. Enhanced anti-tumor activity by the combination of TRAIL/Apo-2L and combretastatin A-4 against human colon cancer cells via induction of apoptosis in vitro and in vivo. Cancer Lett. 1;302(1):11-9. 2011 Mar
• Zhu H, Liu XW, Ding WJ, Xu DQ, Zhao YC, Lu W, He QJ, Yang B*. Up-regulation of death receptor 4 and 5 by celastrol enhances the anti-cancer activity of TRAIL/Apo-2L. Cancer Lett. 2010 Nov 28;297(2):155-64.

• Jing H, Zhou X, Dong X, Cao J, Zhu H, Lou J, Hu Y, He Q, Yang B*. Abrogation of Akt signaling by Isobavachalcone contributes to its anti-proliferative effects towards human cancer cells. Cancer Lett. 2010 Aug 28;294(2):167-77.
• Zhang J, Cao J, Weng Q, Wu R, Yan Y, Jing H, Zhu H, He Q, Yang B*.  Suppression of Hypoxia-Inducible Factor 1α (HIF-1α) by Tirapazamine Is Dependent on eIF2α Phosphorylation Rather Than the mTORC1/4E-BP1 Pathway. PLoS One. 2010 Nov 9; 5(11): e13910.
• Liu XW, Su Y, Zhu H, Cao J, Ding WJ, Zhao YC, He QJ, Yang B*. HIF-1alpha-dependent autophagy protects HeLa cells from fenretinide (4-HPR)-induced apoptosis in hypoxia. Pharmacol Res. 2010 Nov;62(5):416-425.
• Zhu H, Liu XW, Cai TY, Cao J, Tu CX, Lu W, He QJ, Yang B*. Celastrol Acts as a Potent Anti-Metastatic Agent Targeting {beta}1 Integrin and Inhibiting cell-ECM Adhesion, Partially via the p38 MAPK Pathway. J Pharmacol Exp Ther. 2010 Aug;334(2):489-99.

Recent Projects or grants cooperation with industries or government as Study Director

National Science and Technology Major Project”Major New Drug Discovery” Special Program (2009–2011)

National Natural Science Foundation of China  (2011-2013):

The critical role of eIF2α pathway in the anti-tumor activity of bioreductive drugs

National Natural Science Foundation of China  (2009–2011)

The effect of a novel hypoxia-selective compound on the synthesis and post-translational modulation of HIF1a protein

National Natural Science Foundation of China  (2007 –2009)

HIF1-meidated VEGF/Flt1 autocrine system in hypoxia-mediated drug resistance in cancer cells.

Natural Science Foundation of Zhejiang Province  (2005 –2007)

The establishmen of model systems for assessing anti-cancer activity in hypoxia.

Health Bureau Foundation  of Zhejiang Province (2006-2009)

The pharmacological research ona novel anticancer candidate.

Science and Techno;ogy Department Foundation of Zhejiang Provinve (2005-2007)

The pre-clinical research on a novel anticancer candidate MONCPT.

National Natural Science Foundation of China  (2004 –2007) 

The mechanisms of hypoxia-mediated 4-HPR-resistance in Leukemia cells.

Roche R & D Center (China) Ltd.(2006-2012)

In vivo efficacy study for anticancer drugs.

Latitude Pharmaceuticals Inc., San Diego, CA, USA     (December 2003-2010)

New drug formulations screening on animal models

Studies on the Feasibility of a Novel Polysorbate Free Docetaxel Formulation (SDP-014)

Anticancer drug screening on animal models.

Hollis-Eden Pharmaceutical Com ., San Diego, CA, USA  (December 2003-present)

Pharmacokinetic and Tolerance of HE2100 in various Formulations in Rhesus Monkeys.

Pharmacokinetic studies of a single dose of HE3204-004 in Rhesus Monkeys comparing 2 subcutaneous, one oral and one intravenous formulation.

Pharmacokinetic Studies of HE2100 and HE3204 in Rhesus Monkeys After Intramuscular Injections.

Pilot PK and Toxicology Study of HE2100 in Cynomolgus Monkeys.

A pilot Pharmaccokinectic/Pharmacodynamic Study Evaluating HE3204 and HE2100 in Carboplatin Myelosupressed Rhesus Monkeys.

Pharmacokinetic and Tolerance of HE2100 in various Formulations in Rhesus.

Pharmacokinetics of HE2100 in Rhesus Monkeys After Intramuscular Injections of Highly Concentrated Microsuspension Formulation.

Pharmacokinetic studies of a single dose of HE3204-004 in Rhesus monkeys comparing 2 subcutaneous, one oral and on intravenous formulation.

Pharmacokinetic Study of Various HE2100 Analogs in Rhesus Monkeys After Intravenous, Subcutaneous, and Intramuscular Injections.

Pharmacokinetics of HE2100 in Rhesus Monkeys After Intramuscular or Subcutaneous Injections of a Lipoid Formulation.

Pharmacokinetics of HE2100 in Rhesus Monkeys Comparing Three HERF418 Batches

A Pilot Pharmacokinetic/Pharmacodynamic Study Evaluating HE2100 inNormal Healthy Female Rhesus Monkeys.

Pharmacokinetic Study in Rhesus Monkeys After IV, Intramuscular or Oral Administrations Investigating Various HollisEden Pharmaceuticals Compounds.

Pharmacokinetics of HE2100 in Rhesus Monkeys Comparing Five HERF418 and HERF439 Batches.